AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03365609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concomitant therapy
Description: Omeprazole+Amoxicillin+Clarithromycin+Metronidazole
Study NCT00569738 — intervention group
Intervention type: PROCEDURE
Intervention: PET scan with Ga68-DOTANOC
Description: Imaging: PET scan with Ga68-DOTANOC
Study NCT02219490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: Tablet for oral use
Study NCT02219490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: Tablet for oral use
Study NCT02219490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin was provided as 200 mg tablets, and dosed based on weight,1000 to 1200 mg divided twice daily per local label. For example, for participants weighing \< 75 kg, RBV may have been taken orally as 2 tablets in the morning and 3 tablets in the evening which corresponds to a 1000 mg total daily dose. For participants weighing ≥ 75 kg, RBV may have been taken orally as 3 tablets in the morning and 3 tablets in the evening which corresponds to a 1200 mg total daily dose.
Study NCT00261547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: All subjects will be treated with Rituximab 1000 mg (1 g) intravenously on days 1 and 15.
Study NCT03879642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REDCHiP
Description: 10 week video-based telemedicine intervention to reduce hypoglycemia fear
Study NCT00578214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Randomized Midazolam
Description: Midazolam was prepared in a 2 mg/ml cherry flavored syrup. In the randomized arm, patients received a single-dose administration of 5 ml (10 mg) of the midazolam syrup.
Study NCT00578214 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo was prepared as a color- and texture-matched cherry flavored syrup without midazolam.
Study NCT00578214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Local Anesthesia
Description: Lidocaine 1% with 1:100,000 epinephrine
Study NCT00578214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Description: Lidocaine 1% with 1:100,000 epinephrine
Study NCT00578214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthesia
Description: Lidocaine 1% with 1:100,000 epinephrine
Study NCT00578214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prospective Midazolam
Description: Midazolam was prepared in a 2 mg/ml cherry flavored syrup. Dosing in the prospective arm was based on weight (>45 to 77 kg, 10 mg; >77 to 100 kg, 15 mg; greater than or equal to 100 kg, 20 mg). In the prospective arm patients were given additional doses of midazolam as necessary (in 5 mg increments) to achieve and maintain the desired level of anxiolysis.
Study NCT02824003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS-GCGRRx
Description: once weekly dosing for 13 weeks
Study NCT02824003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once weekly dosing for 13 weeks
Study NCT02272517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10-20 mg
Study NCT02272517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram 10-20 mg
Study NCT01002443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Helicobacter pylori eradication
Description: Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days
Study NCT01002443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Omeprazole 20 mg or Rabeprazole 10 mg bid + two placebo (for antibiotics) for 7 days
Study NCT00667693 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: Intubation with Macintosh laryngoscope
Study NCT00667693 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pentax AWS
Description: Intubation with Pentax AWS
Study NCT02970461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gamified Group
Description: See Gamified Group in Arms description.
Study NCT02970461 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: See Control Group in Arms description.
Study NCT03404843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasudil Hydrochloride
Description: 10 mg/mL vial of fasudil hydrochloride. 6 mL (60 mg) of fasudil hydrochloride are added to a 100 mL saline bag for delivery to subjects.
Study NCT03404843 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 100 mL saline bag.
Study NCT00567164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE20/DRSP (BAY86-5300)
Description: Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
Study NCT00567164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EE20/DRSP (YAZ, BAY86-5300)
Description: Fixed package per cycle containing combination tablets containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone (24 per cycle) + tablets without active substance (4 per cycle)
Study NCT01715909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Participants will receive standard dose (30 to 75 milligrams \[mg\]) or triple standard dose (90 to 225 mg) of oseltamivir orally daily for up to maximum of 20 days. Standard dose of oseltamivir according to weight (except infants): 30 mg twice daily for \</= 15 kilograms (kg) body weight participants; 45 mg twice daily for 15 to 23 kg body weight participants; 60 mg twice daily for 23 to 40 kg body weight participants; and 75 mg twice daily for greater than (>) 40 kg body weight participants. Standard dose for infants is 3 mg/kg.
Study NCT06747026 — intervention group
Intervention type: DRUG
Intervention: initial Sequential iRT
Description: For unresectable locally advanced NSCLC, definitive thoracic radiotherapy must have been administered as the initial treatment, with immunotherapy initiated within 90 days after RT.~For de novo metastatic NSCLC, radiotherapy targeting the primary lung tumor or metastatic lesions must have been administered as the initial treatment, with immunotherapy initiated within 90 days.
Study NCT02543216 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sunflower oil
Description: Study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. Thus, approximately 16-28 g (6 E%) LA were provided daily on top of the average intake of approximately 10-12 g (4.5 E%).
Study NCT00545844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: montelukast sodium, 10 mg, one tablet once a day for 8 weeks as add on therapy to usual current asthma controller treatment
Study NCT02506426 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic sinus surgery + Septoplasty
Description: Opening of the paranasal sinuses along with correcting the nasal septum
Study NCT02506426 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Septoplasty alone
Description: Straightening of the nasal septum without opening the paranasal sinuses
Study NCT00001575 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Y-90 Humanized Anti-Tac
Description: 10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).
Study NCT00001575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium-DTPA
Description: Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body
Study NCT03736785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC
Study NCT03736785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC
Study NCT04160689 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: implantology
Description: placing of implant
Study NCT01539603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting balloon + Bare metal stent
Description: PCI using Sequent Please and then Coroflex Blue
Study NCT01539603 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug eluting stent (Zotarolimus-eluting stent)
Description: conventional PCI using Endeavor Integrity
Study NCT02095158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline HCL Cream 1.0%
Description: Oxymetazoline HCL Cream 1.0% applied to the face once daily for 52 weeks.
Study NCT02770144 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Access to Referral to Social Services
Study NCT02770144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to Referral to Social Services
Study NCT00116480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 600 mcg of sublingual misoprostol
Study NCT00116480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: 600 mcg of sublingual misoprostol
Study NCT04312568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fadanafil
Description: Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose
Study NCT04312568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose
Study NCT03518983 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dornier Aries2 device
Description: The Dornier Aries2 device and will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft and the 2 crura(two sites).
Study NCT03518983 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Dornier Aries2 device (sham probe)
Description: The Dornier Aries2 device and will be used for the purpose of the study but the active probe will be replaced by an identical sham probe.
Study NCT04238104 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: it's only observational study. No interventions.
Study NCT03693755 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In-plane Group
Description: Placement of femoral nerve catheter under ultrasound control
Study NCT03693755 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Out-of-plane Group
Description: Placement of femoral nerve catheter under ultrasound control
Study NCT03198546 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GPC3 and/or TGFβ targeting CAR-T cells
Description: Engineering GPC3 or/and TGFβ targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Tigit secreting vector into T cells with knockdown of PD1/HPK1, which are isolated from patients with advanced HCC, and then transfusing them back the patients.
Study NCT02537392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B Complex and Folic Acid
Description: Daily oral dose containing 2 mg vitamin B1, 2 mg vitamin B2, 2 mg vitamin B6, 2 μg vitamin B12, 2 mg calcium pantothenate, 15 mg nicotinamide and 0.4 mg folic acid.
Study NCT02537392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron and Folic Acid
Description: Daily oral dose of 60 mg iron and 0.4 mg folic acid.
Study NCT02537392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Daily oral dose of 0.4 mg folic acid.
Study NCT01501214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atosiban
Description: Patients in the atosiban group will receive intravenous atosiban 30 min before the transfer with a bolus dose of 6.75 mg, and the infusion will be continued with an infusion rate of 18 mg/h. After performing ET, the dose of atosiban will be reduced to 6 mg/h and the infusion will be continued for 2 hours (total administered dose: 37.5 mg). Those in the placebo group will receive normal saline only.
Study NCT01501214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline given
Study NCT02380729 — intervention group
Intervention type: GENETIC
Intervention: Gene Panel Sequencing
Description: Enrichment for and panel sequencing of 2942 disease genes listed in the Online Mendelian Inheritance of Man (OMIM) database.
Study NCT02380729 — intervention group
Intervention type: GENETIC
Intervention: Whole Genome Sequencing (WGS)
Description: Whole Genome Sequencing of the index case and of both parents in the event that Gene Panel Sequencing did not identify a disease-causing mutation.
Study NCT03877471 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Cell therapy
Description: Ovary injection with MSC-like cells through transvaginal ultrasound,3 injection points for each ovary.
Study NCT01174316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoVPAP™
Description: Automatically titrated non-invasive ventilator, with target gross alveolar ventilation, end expiratory positive pressure, and back up respiratory rate determined by the clinician based on height and weight. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
Study NCT01174316 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VPAPIIIST-A™
Description: Standard non-invasive ventilator, with inspiratory and expiratory positive pressure determined by the healthcare professional. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
Study NCT04181632 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Buzzy Bee with Ice pack
Description: Buzzy uses natural pain relief to block needle pain for blood draws and shots. This intervention will be used with an ice pack.
Study NCT04181632 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Buzzy Bee without Ice pack
Description: Buzzy uses natural pain relief to block needle pain for blood draws and shots. This intervention will be used without an ice pack.
Study NCT04181632 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shot Blocker
Description: Shot Blocker is a device that instantly alleviates the pain and anxiety of needle injections when pressed firmly against the skin at the injection site.
Study NCT04159948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate drink
Description: This is a commercially available pre-op carbohydrate drink used in enhanced recovery programmes.
Study NCT04159948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate drink
Description: This is a commercially available pre-op carbohydrate drink used in enhanced recovery programmes.
Study NCT01473719 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: motivational intervention
Description: 7-session individual motivationally-based intervention
Study NCT01518335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma injection
Description: 50ml of blood drawn into a 60cc with 10cc of anticoagulant is processed using MAGELLAN® Autologous Platelet (Arteriocyte Medical Systems, Cleveland Ohio)to separate out approximately 3-6 cc of platelet rich plasma, which is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
Study NCT01518335 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo/Standard of Care
Description: 50ml of blood is drawn into a 60cc with 10cc of anticoagulant and is then discarded. 4 cc of saline solution is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
Study NCT01473719 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: health education
Description: 7 individual sessions focusing on health education
Study NCT04469218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SafeBreak Vascular
Description: SafeBreak Vascular is a breakaway connector that screws into peripheral IV lines using luer connectors on each end. The device is designed to separate when a harmful force is placed on an IV line. Upon separation, valves on each side of the device close. On the patient side of the device, the valve closes to prevent the loss of blood and on the IV pump side of the device, the valve closes to stop the flow of medication. The valve closing on the IV pump side of the line causes the pump's occlusion alarm to sound and notify nurses that the IV needs attention. The nurse is able to throw away the separated SafeBreak Vascular, install a new SafeBreak, and restart the patient's infusion without the negative cascade of events that can occur when a peripheral IV fails.
Study NCT00832884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lacosamide
Description: 0.7 mg/kg (up to maximum of 50 mg) x 5 subjects x 30 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 30 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 30 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 30 minutes.~0.7 mg/kg (up to a maximum of 50 mg) x 5 subjects x 15 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 15 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 15 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 15 minutes
Study NCT06747026 — intervention group
Intervention type: DRUG
Intervention: initial Concurrent iRT
Description: For unresectable locally advanced NSCLC, definitive thoracic radiotherapy must have been administered as the initial treatment, with immunotherapy concurrently with RT.~For de novo metastatic NSCLC, radiotherapy targeting the primary lung tumor or metastatic lesions must have been administered as the initial treatment, with immunotherapy concurrently with RT.
Study NCT04546269 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fully-guided vs. conventionally guided implant placement
Description: Patients randomized to implant placement planned virtually based on a CBCT and a surface scan vs. implant placement based on a wax-up on gypsum casts
Study NCT06747026 — intervention group
Intervention type: DRUG
Intervention: RT with maintenance of ICI
Description: For post-treatment progressive NSCLC, salvage radiotherapy performed during immunotherapy.
Study NCT00770679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipitor
Description: 80 mg everyday (QD) for 3 weeks
Study NCT04546269 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fully-guided vs. conventionally guided implant placement
Description: Patients randomized to implant placement planned virtually based on a CBCT and a surface scan vs. implant placement based on a wax-up on gypsum casts
Study NCT00470743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Study NCT00470743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indomethacin
Study NCT00966966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAM-531 and gemfibrozil
Description: 2 single doses of 5 mg SAM-531 (capsules) a daily dose of 1200 mg Gemfibrozil (one tablet of 600mg at approximately 8 a.m. and one tablet of 600 mg at approximately 6 p.m.) for 14 days
Study NCT04590651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Routine phacoemulsification cataract surgery using the Alcon Centurion® device.
Study NCT04590651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery with extra anterior chamber angle aspiration
Description: Routine phacoemulsification cataract surgery using the Alcon Centurion® device. At the end of the case a one minute extra anterior chamber angle aspiration will be preformed after the removal of the viscoelastic agent.
Study NCT02760381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBI + Acetic Acid (AA)
Description: Patients belonging to the Routine colonoscopy Cohort will receive NBI + Acetic Acid (AA) chromoendoscopy for optical predictions of colonic polyps.
Study NCT06747026 — intervention group
Intervention type: DRUG
Intervention: RT after discontinuation of ICI
Description: For post-treatment progressive NSCLC, salvage radiotherapy performed during within 90 days after the cessation of immunotherapy.
Study NCT02485158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: This is a within-subjects, double-blind, placebo controlled design. We administered oral THC to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
Study NCT02485158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMP
Description: This is a within-subjects, double-blind, placebo controlled design. We administered AMP to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
Study NCT00839501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium
Description: 40 mEq twice daily in pill form during the first 3-day inpatient visit, followed by 40 mEq twice daily in liquid form during the first 18-week treatment period, as is randomly scheduled, and continued during the second 18-week treatment period as long as there are no limiting side effects
Study NCT00839501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: 250 mg twice daily, orally, during the second 3-day inpatient visit and during the second 18-week treatment period, as is randomly scheduled